Ensysce Biosciences (ENSC) SEC Filings: History & Chart

Ensysce Biosciences, Inc.(ENSC)

Biotechnology · La Jolla, CA

$0.42+0.01 (+1.26%)

Delayed quote: Oct 6, 2026, 10:35 AM EDT

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.

La Jolla, CA

9 employees

www.ensysce.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: D. Lynn Kirkpatrick

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 29, 2026	Sep 29, 2026	View filing
8-K	Aug 25, 2026	Aug 25, 2026	View filing
8-K	Aug 24, 2026	Aug 24, 2026	View filing
D	Aug 20, 2026	Aug 20, 2026	View filing
SC 13D/A	Aug 18, 2026	Aug 18, 2026	View filing
4	Aug 18, 2026	Aug 18, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
3	Aug 10, 2026	Aug 10, 2026	View filing
8-K/A	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Jul 15, 2026	Jul 15, 2026	View filing
EFFECT	Jun 26, 2026	Jun 29, 2026	View filing
S-3	Jun 4, 2026	Jun 4, 2026	View filing
8-K	May 22, 2026	May 22, 2026	View filing
10-Q	May 15, 2026	May 15, 2026	View filing
8-K	May 15, 2026	May 15, 2026	View filing
S-8	Apr 30, 2026	Apr 30, 2026	View filing
EFFECT	Apr 15, 2026	Apr 16, 2026	View filing
CORRESP	Apr 14, 2026	Apr 14, 2026	View filing
UPLOAD	Apr 13, 2026	Apr 13, 2026	View filing
S-3	Apr 9, 2026	Apr 8, 2026	View filing
8-K	Apr 8, 2026	Apr 7, 2026	View filing
8-K	Apr 3, 2026	Apr 3, 2026	View filing
10-K	Mar 30, 2026	Mar 30, 2026	View filing
8-K	Mar 30, 2026	Mar 30, 2026	View filing
8-K	Mar 30, 2026	Mar 27, 2026	View filing
8-K	Mar 23, 2026	Mar 23, 2026	View filing
8-K	Feb 27, 2026	Feb 27, 2026	View filing
8-K	Jan 8, 2026	Jan 8, 2026	View filing

SEC Filings

Recent Filings